<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00057941</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-03148</org_study_id>
    <secondary_id>NCI-2012-03148</secondary_id>
    <secondary_id>CDR0000285631</secondary_id>
    <secondary_id>U10CA021115</secondary_id>
    <secondary_id>E4101</secondary_id>
    <secondary_id>E4101</secondary_id>
    <nct_id>NCT00057941</nct_id>
  </id_info>
  <brief_title>Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer</brief_title>
  <official_title>A Randomized Phase II Trial of Combination Anastrozole (NSC #719344) Plus ZD1839 (Iressa, NSC #715055, IND #61187) and of Combination Fulvestrant (NSC #719276) Plus ZD1839 in the Treatment of Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This randomized phase II trial is studying how well giving gefitinib together with
      anastrozole works compared to giving gefitinib together with fulvestrant in treating
      postmenopausal women with recurrent or metastatic breast cancer. Estrogen can stimulate the
      growth of breast cancer cells. Hormone therapy using anastrozole and fulvestrant may fight
      breast cancer by blocking the use of estrogen. Gefitinib (ZD1839) may stop the growth of
      cancer cells by blocking the enzymes necessary for their growth. It is not yet known whether
      gefitinib is more effective when combined with anastrozole or fulvestrant in treating breast
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Evaluate the antitumor activity of anastrozole given in combination with the EGFR tyrosine
      kinase inhibitor ZD1839, and of fulvestrant given in combination with the EGFR tyrosine
      kinase inhibitor ZD1839.

      II. Evaluate the safety of anastrozole given in combination with ZD1839 and fulvestrant given
      in combination with ZD1839.

      III. Evaluate the interaction of biological characteristics that predict for response of
      breast cancer to treatment with anastrozole and ZD1839 and with fulvestrant and ZD1839.

      OUTLINE: This is a randomized, open-label study. Patients are stratified according to prior
      hormonal therapy (yes vs. no) and dominant site of disease (soft tissue/lymph nodes vs. bone
      vs. visceral). Patients are randomized to 1 of 2 treatment arms.

      Arm I: Patients receive oral anastrozole and oral gefitinib once daily on days 1-28.

      Arm II: Patients receive fulvestrant intramuscularly on day 1 and oral gefitinib once daily
      on days 1-28.

      Courses in both arms repeat every 28 days in the absence of disease progression or
      unacceptable toxicity.

      Patients are followed every 3 months for 2 years and then every 6 months for 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Benefit Rate</measure>
    <time_frame>assessed every 3 cycles while on treatment, assessed every 3 months when follow up &lt;2 years, every 6 months between 2-3 years,no specific requirements after 3 years</time_frame>
    <description>Clinical benefit = complete response (CR), partial response (PR), or stable disease (SD) lasting for at least 6 months, assessed per Response Evaluation Criteria of Solid Tumor (RECIST).CR=disappearance of all target and non-target lesions. PR= disappearance of or at least 30% decrease in the sum of the longest diameters of target lesions, with non-progressive disease in non-target lesions. SD= sum of the longest diameters of target lesions decrease &lt;30% or increase &lt;20%, with non-progressive disease in non-target lesions. 141 eligible, treated patients were included.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Estrogen Receptor-positive Breast Cancer</condition>
  <condition>Progesterone Receptor-positive Breast Cancer</condition>
  <condition>Recurrent Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (anastrozole, gefitinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral anastrozole and oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (fulvestrant, gefitinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fulvestrant intramuscularly on day 1 and oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anastrozole</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I (anastrozole, gefitinib)</arm_group_label>
    <other_name>ANAS</other_name>
    <other_name>Arimidex</other_name>
    <other_name>ICI-D1033</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I (anastrozole, gefitinib)</arm_group_label>
    <arm_group_label>Arm II (fulvestrant, gefitinib)</arm_group_label>
    <other_name>Iressa</other_name>
    <other_name>ZD 1839</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fulvestrant</intervention_name>
    <description>Given intramuscularly</description>
    <arm_group_label>Arm II (fulvestrant, gefitinib)</arm_group_label>
    <other_name>Faslodex</other_name>
    <other_name>ICI 182,780</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (anastrozole, gefitinib)</arm_group_label>
    <arm_group_label>Arm II (fulvestrant, gefitinib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have estrogen and/or progesterone receptor positive histologically
             confirmed adenocarcinoma of the breast with measurable recurrent or metastatic
             carcinoma of the breast

          -  Baseline measurements and evaluations of involved sites should be performed as close
             as possible to study entry, but must be within 4 weeks prior to randomization

          -  Patients with available tissue blocks from either the primary or metastatic site must
             submit the tissue for EGFR analysis

          -  All patients must be postmenopausal females defined by:

               -  Prior bilateral oophorectomy or bilateral ovarian irradiation

               -  No menstrual period for 12 months or longer. If age 55 years or less and on
                  tamoxifen within the prior 6 months, must have an estradiol level in the
                  postmenopausal range

          -  Patients must not have had more than 2 prior chemotherapy regimens for metastatic
             disease and no chemotherapy within 3 weeks prior to randomization; no concurrent
             chemotherapy is allowed while on protocol therapy

          -  Patients must not have prior hormonal therapy for metastatic disease; no prior therapy
             in the adjuvant setting with an estrogen receptor down-regulator (e.g. fulvestrant) or
             an aromatase inhibitor (e.g. anastrozole, letrozole, exemestane, aminoglutethamide);
             non-protocol concurrent hormonal therapy is not allowed

          -  Patients must not have had prior therapy with agents that target EGFR

          -  Previous, but not concomitant, therapy with trastuzumab (Herceptin) is allowed;
             patients must not receive trastuzumab (Herceptin) within 3 weeks prior to
             randomization

          -  Patients must have ECOG performance status of 0, 1, or 2

          -  Neutrophils &gt;= 1500/mm^3

          -  Platelets &gt;= 100,000/mm^3

          -  Bilirubin =&lt; 1.25 x upper limit of normal

          -  SGPT (ALT) and SGOT (AST) =&lt; 2.5 x upper limit of normal if no demonstrable liver
             metastases or =&lt; 5 times upper limit of normal in the presence of liver metastases

          -  Calculated creatinine clearance &gt;= 30ml/min

          -  INR, PT and PTT within normal range

          -  Patients must not be receiving therapy with anticoagulants or have other
             contraindication to i.m. injections

          -  Patients must not have a history of central nervous system metastasis

          -  Patients may receive concurrent radiation therapy to painful sites of boney disease or
             areas of impending fracture as long as the radiation therapy is initiated prior to
             study entry and sites of measurable disease outside the radiation therapy port are
             available to follow; patient who have received prior radiation therapy must have
             recovered from toxicity of the prior radiation therapy

          -  Patients must not take the following medications that may alter ZD1839
             pharmacokinetics while enrolled in this trial: phenytoin, carbamazapine,
             phenobarbitol, rifampicin, and St. John's Wort, oxcarbazepine, rifapentine, modafinil,
             and griseofulvin

          -  Patients age =&lt; 55 years must not be receiving LHRH agonists or antagonists within 3
             months prior to randomization

          -  Patients who have an ocular inflammation or infection should be fully treated before
             entry into the trial; patients with a neuropathic keratopathy or diabetes or those
             with anterior basement membrane disease must be advised of the need for frequent
             opthalmalogic exams

          -  Patients who continue to wear contact lenses must be advised that they have an
             increased risk of ocular events; the decision to wear contact lenses should be
             discussed with the patient's treating oncologist and ophthalmologist

          -  Patients must not suffer from medical or psychiatric conditions that would interfere
             with protocol compliance, the ability to provide informed consent, or assessment of
             response or anticipated toxicities

          -  Patients must be disease-free of prior invasive malignancies for &gt; 5 years with the
             exception of curatively-treated basal cell or squamous cell carcinoma of the skin or
             carcinoma in situ of the cervix
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Carlson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Cooperative Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eastern Cooperative Oncology Group</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Peru</country>
    <country>South Africa</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2003</study_first_submitted>
  <study_first_submitted_qc>April 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2003</study_first_posted>
  <results_first_submitted>April 11, 2011</results_first_submitted>
  <results_first_submitted_qc>April 11, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 6, 2011</results_first_posted>
  <last_update_submitted>April 22, 2014</last_update_submitted>
  <last_update_submitted_qc>April 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study opened on September 16, 2003 and closed on May 29, 2007, with final accrual of 148 patients, 74 on each arm. Patients were accrued through ECOG group.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Anastrozole and ZD1839)</title>
          <description>Patients receive oral anastrozole and oral gefitinib once daily on days 1-28.</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Fulvestrant and ZD1839)</title>
          <description>Patients receive fulvestrant intramuscularly on day 1 and oral gefitinib once daily on days 1-28.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>still on treatment</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>insurance, symptomatic deterioration</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Anastrozole and ZD1839)</title>
          <description>Patients receive oral anastrozole and oral gefitinib once daily on days 1-28.</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Fulvestrant and ZD1839)</title>
          <description>Patients receive fulvestrant intramuscularly on day 1 and oral gefitinib once daily on days 1-28.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
            <count group_id="B2" value="69"/>
            <count group_id="B3" value="141"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="34" upper_limit="90"/>
                    <measurement group_id="B2" value="63" lower_limit="35" upper_limit="91"/>
                    <measurement group_id="B3" value="59" lower_limit="34" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peru</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Benefit Rate</title>
        <description>Clinical benefit = complete response (CR), partial response (PR), or stable disease (SD) lasting for at least 6 months, assessed per Response Evaluation Criteria of Solid Tumor (RECIST).CR=disappearance of all target and non-target lesions. PR= disappearance of or at least 30% decrease in the sum of the longest diameters of target lesions, with non-progressive disease in non-target lesions. SD= sum of the longest diameters of target lesions decrease &lt;30% or increase &lt;20%, with non-progressive disease in non-target lesions. 141 eligible, treated patients were included.</description>
        <time_frame>assessed every 3 cycles while on treatment, assessed every 3 months when follow up &lt;2 years, every 6 months between 2-3 years,no specific requirements after 3 years</time_frame>
        <population>141 eligible and treated patients, 72 on Arm I (Anastrozole and ZD1839) and 69 on Arm II (Fulvestrant and ZD1839)</population>
        <group_list>
          <group group_id="O1">
            <title>Anastrozole and ZD1839</title>
          </group>
          <group group_id="O2">
            <title>Fulvestrant and ZD1839</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Rate</title>
          <description>Clinical benefit = complete response (CR), partial response (PR), or stable disease (SD) lasting for at least 6 months, assessed per Response Evaluation Criteria of Solid Tumor (RECIST).CR=disappearance of all target and non-target lesions. PR= disappearance of or at least 30% decrease in the sum of the longest diameters of target lesions, with non-progressive disease in non-target lesions. SD= sum of the longest diameters of target lesions decrease &lt;30% or increase &lt;20%, with non-progressive disease in non-target lesions. 141 eligible, treated patients were included.</description>
          <population>141 eligible and treated patients, 72 on Arm I (Anastrozole and ZD1839) and 69 on Arm II (Fulvestrant and ZD1839)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="33" upper_limit="57"/>
                    <measurement group_id="O2" value="41" lower_limit="29" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Assessed each cycle (4 weeks) while on treatment and for 30 days after the end of treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Anastrozole and ZD1839)</title>
          <description>Patients receive oral anastrozole and oral gefitinib once daily on days 1-28.</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Fulvestrant and ZD1839)</title>
          <description>Patients receive fulvestrant intramuscularly on day 1 and oral gefitinib once daily on days 1-28.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Diarrhea w/o prior colostomy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>AST increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection w/o neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Lymphatics-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Elevated Partial thromboplastin time (PTT)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Elevated Prothrombin Time (PT)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint,muscle, bone-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Tearing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Ureteral obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Vaginitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome (ARDS)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand-foot reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Skin-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Thrombosis/Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Diarrhea w/o prior colostomy</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Pain-other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>AST increased</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection w/o neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Elevated Partial Thromboplastin Time (PTT)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Elevated Prothrombin Time (PT)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy-motor</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Hand-foot reaction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Nail change</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Skin-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Statistician</name_or_title>
      <organization>Eastern Cooperative Oncology Group (ECOG) Statistical Office</organization>
      <phone>617-632-3012</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

